Asparaginase dosing for acute lymphoblastic leukemia: more questions than answers - PubMed (original) (raw)

Asparaginase dosing for acute lymphoblastic leukemia: more questions than answers

Etan Orgel. Haematologica. 2025.

No abstract available

PubMed Disclaimer

Figures

Figure 1.

Figure 1.

Deriving clues from contrasting cohorts to optimize asparaginase use. SJCRH: St. Jude Children’s Research Hospital; ALL: acute lymphoblastic leukemia; HR: high risk; PEG: pegaspargase.

References

    1. Panetta JC, Ashcraft E, Jeha S, et al. Changes in asparaginase exposure and toxicity profiles in obese pediatric acute lymphoblastic leukemia patients. Haematologica. 2025;110(8):1849-1853. -PubMed
    1. Maese L, Rau RE. Current use of asparaginase in acute lymphoblastic leukemia/lymphoblastic lymphoma. Front Pediatr. 2022;10:902117. -PMC -PubMed
    1. Advani AS, Larsen E, Laumann K, et al. Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia. Blood Adv. 2021;5(2):504-512. -PMC -PubMed
    1. Orgel E, Militano O, Chen Z, et al. Effects of age, obesity, and body surface area on asparaginase-associated toxicities during acute lymphoblastic leukemia induction therapy: a report from the Children’s Oncology Group. J Clin Oncol. 2022;40(16_suppl):7000.
    1. Egnell C, Heyman M, Jónsson ÓG, et al. Obesity as a predictor of treatment-related toxicity in children with acute lymphoblastic leukaemia. Br J Haematol. 2022;196(5):1239-1247. -PubMed

LinkOut - more resources